KR20070085674A - 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법 - Google Patents
약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법 Download PDFInfo
- Publication number
- KR20070085674A KR20070085674A KR1020077012489A KR20077012489A KR20070085674A KR 20070085674 A KR20070085674 A KR 20070085674A KR 1020077012489 A KR1020077012489 A KR 1020077012489A KR 20077012489 A KR20077012489 A KR 20077012489A KR 20070085674 A KR20070085674 A KR 20070085674A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- growth
- vancomycin
- antimicrobial agent
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 36
- 208000035473 Communicable disease Diseases 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims description 38
- 229940079593 drug Drugs 0.000 title claims description 31
- 238000002648 combination therapy Methods 0.000 title claims description 17
- 108010059993 Vancomycin Proteins 0.000 claims abstract description 62
- 229960003165 vancomycin Drugs 0.000 claims abstract description 55
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims abstract description 55
- 239000000203 mixture Substances 0.000 claims abstract description 52
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims abstract description 51
- 208000015181 infectious disease Diseases 0.000 claims abstract description 46
- 229960004755 ceftriaxone Drugs 0.000 claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 37
- 239000002904 solvent Substances 0.000 claims abstract description 18
- 229930186147 Cephalosporin Natural products 0.000 claims abstract description 14
- 108010015899 Glycopeptides Proteins 0.000 claims abstract description 14
- 102000002068 Glycopeptides Human genes 0.000 claims abstract description 14
- 229940124587 cephalosporin Drugs 0.000 claims abstract description 14
- 150000001780 cephalosporins Chemical class 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 238000007911 parenteral administration Methods 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 238000001556 precipitation Methods 0.000 claims abstract description 9
- 239000002552 dosage form Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 239000004599 antimicrobial Substances 0.000 claims description 60
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims description 53
- 238000011282 treatment Methods 0.000 claims description 36
- 229930182555 Penicillin Natural products 0.000 claims description 20
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 230000000845 anti-microbial effect Effects 0.000 claims description 15
- 239000003981 vehicle Substances 0.000 claims description 13
- -1 Penam penicillins Chemical class 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 229960000479 ceftriaxone sodium Drugs 0.000 claims description 7
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical group [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 229960001572 vancomycin hydrochloride Drugs 0.000 claims description 7
- LCTORFDMHNKUSG-XTTLPDOESA-N vancomycin monohydrochloride Chemical compound Cl.O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 LCTORFDMHNKUSG-XTTLPDOESA-N 0.000 claims description 7
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 229960003022 amoxicillin Drugs 0.000 claims description 6
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 6
- 229960001484 edetic acid Drugs 0.000 claims description 6
- 229960003085 meticillin Drugs 0.000 claims description 6
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- BVCKFLJARNKCSS-DWPRYXJFSA-N temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 claims description 5
- 229960001114 temocillin Drugs 0.000 claims description 5
- 150000003952 β-lactams Chemical class 0.000 claims description 5
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000011261 inert gas Substances 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 150000002960 penicillins Chemical class 0.000 claims description 4
- 229960003330 pentetic acid Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000012859 sterile filling Methods 0.000 claims description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 108010013198 Daptomycin Proteins 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 108010053950 Teicoplanin Proteins 0.000 claims description 3
- 239000003708 ampul Substances 0.000 claims description 3
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims description 3
- 229960005484 daptomycin Drugs 0.000 claims description 3
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 229960001608 teicoplanin Drugs 0.000 claims description 3
- WKJGTOYAEQDNIA-IOOZKYRYSA-N (6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 WKJGTOYAEQDNIA-IOOZKYRYSA-N 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims description 2
- 229930195708 Penicillin V Natural products 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 229960004821 amikacin Drugs 0.000 claims description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 2
- 229960000723 ampicillin Drugs 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- 229950006334 apramycin Drugs 0.000 claims description 2
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 claims description 2
- 229940090047 auto-injector Drugs 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 claims description 2
- 229960003669 carbenicillin Drugs 0.000 claims description 2
- 229960000484 ceftazidime Drugs 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 2
- 238000002309 gasification Methods 0.000 claims description 2
- 229960002518 gentamicin Drugs 0.000 claims description 2
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 claims description 2
- 229960000198 mezlocillin Drugs 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- 229910052756 noble gas Inorganic materials 0.000 claims description 2
- 150000002835 noble gases Chemical class 0.000 claims description 2
- 229960001019 oxacillin Drugs 0.000 claims description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 claims description 2
- 229940056360 penicillin g Drugs 0.000 claims description 2
- 229940056367 penicillin v Drugs 0.000 claims description 2
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 2
- 229960002292 piperacillin Drugs 0.000 claims description 2
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims description 2
- 229960000268 spectinomycin Drugs 0.000 claims description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims description 2
- 229960005322 streptomycin Drugs 0.000 claims description 2
- 239000008215 water for injection Substances 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 2
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 claims 1
- LOYTUFQOTJYLPX-UHFFFAOYSA-N C1=CC=[Si]C=C1 Chemical compound C1=CC=[Si]C=C1 LOYTUFQOTJYLPX-UHFFFAOYSA-N 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229960001139 cefazolin Drugs 0.000 claims 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims 1
- 229960004261 cefotaxime Drugs 0.000 claims 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- JVKAWJASTRPFQY-UHFFFAOYSA-N n-(2-aminoethyl)hydroxylamine Chemical compound NCCNO JVKAWJASTRPFQY-UHFFFAOYSA-N 0.000 claims 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 claims 1
- 229960000515 nafcillin Drugs 0.000 claims 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000008174 sterile solution Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 description 49
- 238000007689 inspection Methods 0.000 description 20
- 229940049954 penicillin Drugs 0.000 description 15
- 239000003242 anti bacterial agent Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 241000191967 Staphylococcus aureus Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 206010041925 Staphylococcal infections Diseases 0.000 description 9
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 9
- 210000001508 eye Anatomy 0.000 description 8
- 201000009906 Meningitis Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000191940 Staphylococcus Species 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 241001430312 Amycolatopsis orientalis Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241000606790 Haemophilus Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010027202 Meningitis bacterial Diseases 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 206010035148 Plague Diseases 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 206010037596 Pyelonephritis Diseases 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 201000009904 bacterial meningitis Diseases 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 206010034674 peritonitis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000590020 Achromobacter Species 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 2
- 241000588986 Alcaligenes Species 0.000 description 2
- 206010060968 Arthritis infective Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 2
- 206010006500 Brucellosis Diseases 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 208000004145 Endometritis Diseases 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 206010023424 Kidney infection Diseases 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241000589902 Leptospira Species 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 241000187654 Nocardia Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 241000191992 Peptostreptococcus Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 241000589886 Treponema Species 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 238000011203 antimicrobial therapy Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940041007 third-generation cephalosporins Drugs 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- VJYOITCEUJNXCK-UHFFFAOYSA-N 11-oxa-3,17-diazabicyclo[22.4.0]octacosa-1(24),2,4,6,8,12,14,16,18,20,22,25,27-tridecaene-28-carboxylic acid Chemical compound C1=NC=CC=CC=CCOC=CC=CC=NC=CC=CC=CC2=C1C(=CC=C2)C(=O)O VJYOITCEUJNXCK-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010056519 Abdominal infection Diseases 0.000 description 1
- 241000726119 Acidovorax Species 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000187362 Actinomadura Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241000190801 Afipia Species 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241001135163 Arcobacter Species 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010004016 Bacterial diarrhoea Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 206010044583 Bartonella Infections Diseases 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 208000004020 Brain Abscess Diseases 0.000 description 1
- 241000131407 Brevundimonas Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000190890 Capnocytophaga Species 0.000 description 1
- 208000028737 Carrion disease Diseases 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000589519 Comamonas Species 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 241000605314 Ehrlichia Species 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 206010014684 Endocarditis staphylococcal Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010015146 Erysipeloid Diseases 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010061974 Gastrointestinal obstruction Diseases 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000203751 Gordonia <actinomycete> Species 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 201000008327 Haverhill fever Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001454354 Kingella Species 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000186809 Kurthia Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000004023 Legionellosis Diseases 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241001453444 Leptonema <bacteria> Species 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 241000589323 Methylobacterium Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000041810 Mycetoma Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000224436 Naegleria Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010058803 Oesophageal infection Diseases 0.000 description 1
- 208000010598 Oroya fever Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033119 Ovarian abscess Diseases 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000206591 Peptococcus Species 0.000 description 1
- 206010071301 Perihepatitis Diseases 0.000 description 1
- 241000607000 Plesiomonas Species 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 206010036422 Postpartum sepsis Diseases 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 208000020264 Puerperal Infection Diseases 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 241000232299 Ralstonia Species 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 241001453443 Rothia <bacteria> Species 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 241000589973 Spirochaeta Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042175 Streptobacillary fever Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000202898 Ureaplasma Species 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910052768 actinide Inorganic materials 0.000 description 1
- 150000001255 actinides Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- ZEASXVYVFFXULL-UHFFFAOYSA-N amezinium metilsulfate Chemical compound COS([O-])(=O)=O.COC1=CC(N)=CN=[N+]1C1=CC=CC=C1 ZEASXVYVFFXULL-UHFFFAOYSA-N 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 230000000935 anti-streptococcal effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 201000006824 bubonic plague Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000009058 cervical adenitis Diseases 0.000 description 1
- 208000012751 cervical lymphadenitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- FDRNWTJTHBSPMW-BBJOQENWSA-L disodium;(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-1-oxidoethylidene]amino]-3-[(2-methyl-5,6-dioxo-1h-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-BBJOQENWSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000009112 empiric therapy Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000037939 human monocytotropic ehrlichiosis Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000000511 intracranial abscess Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 201000001231 mediastinitis Diseases 0.000 description 1
- 201000004015 melioidosis Diseases 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 208000010453 mesenteric lymphadenitis Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 208000010563 rat-bite fever Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000017810 streptobacillary rat-bite fever Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- UBCKGWBNUIFUST-YHYXMXQVSA-N tetrachlorvinphos Chemical compound COP(=O)(OC)O\C(=C/Cl)C1=CC(Cl)=C(Cl)C=C1Cl UBCKGWBNUIFUST-YHYXMXQVSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN308DE2005 | 2005-02-14 | ||
| IN308/DEL/2005 | 2005-02-14 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097006944A Division KR20090052893A (ko) | 2005-02-14 | 2006-02-08 | 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070085674A true KR20070085674A (ko) | 2007-08-27 |
Family
ID=36337659
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077012489A Ceased KR20070085674A (ko) | 2005-02-14 | 2006-02-08 | 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법 |
| KR1020097006944A Withdrawn KR20090052893A (ko) | 2005-02-14 | 2006-02-08 | 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097006944A Withdrawn KR20090052893A (ko) | 2005-02-14 | 2006-02-08 | 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7960337B2 (enExample) |
| EP (1) | EP1848413B1 (enExample) |
| JP (1) | JP4918502B2 (enExample) |
| KR (2) | KR20070085674A (enExample) |
| CN (1) | CN101080221A (enExample) |
| AU (1) | AU2006213441B2 (enExample) |
| BR (1) | BRPI0607168A2 (enExample) |
| CA (1) | CA2597812C (enExample) |
| ES (1) | ES2482700T3 (enExample) |
| MX (1) | MX2007009754A (enExample) |
| NZ (1) | NZ555077A (enExample) |
| PT (1) | PT1848413E (enExample) |
| UA (1) | UA91208C2 (enExample) |
| WO (1) | WO2006085337A1 (enExample) |
| ZA (1) | ZA200704393B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080227732A1 (en) * | 2005-05-13 | 2008-09-18 | Venus Remedies Limited | Treatment and Control of Severe Infections Including Cystic Fibrosis |
| CN101129383B (zh) * | 2006-08-25 | 2014-04-02 | 天津和美生物技术有限公司 | 含氨基糖苷类抗生素的抗生素复方 |
| CN101129382B (zh) * | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| CN101129381B (zh) * | 2006-08-25 | 2012-02-01 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和离子螯合剂的抗生素复方 |
| GB2459126A (en) * | 2008-04-10 | 2009-10-14 | Peter Wilson | Antimicrobial agent |
| CN102548552B (zh) * | 2009-07-24 | 2016-06-01 | 田纳西大学研究基金会 | 作为抗结核剂的大观霉素酰胺 |
| PT2504353T (pt) * | 2009-11-23 | 2018-10-18 | Cubist Pharmaceuticals Llc | Composições de lipopéptido e métodos relacionados |
| US8709310B2 (en) | 2011-01-05 | 2014-04-29 | Hospira, Inc. | Spray drying vancomycin |
| ITLO20110001A1 (it) * | 2011-05-03 | 2012-11-04 | Fisiopharma Srl | Flaconi di vancomicina cloroidrata con stabilità migliorata |
| RU2491921C1 (ru) * | 2012-07-11 | 2013-09-10 | Общество с ограниченной ответственностью "Опытно-технологическая фирма "Этрис" | Способ лечения мастита у коров в сухостойный период |
| WO2014152996A1 (en) | 2013-03-14 | 2014-09-25 | Cubist Pharmaceuticals, Inc. | Crystalline form of a beta-lactamase inhibitor |
| PE20160048A1 (es) * | 2013-03-15 | 2016-02-12 | Merck Sharp & Dohme | Composiciones antibioticas de ceftolozano |
| US20140274996A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Tazobactam and ceftolozane antibiotic compositions |
| US9297295B2 (en) | 2013-03-15 | 2016-03-29 | Scuderi Group, Inc. | Split-cycle engines with direct injection |
| US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
| CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
| WO2015035376A2 (en) | 2013-09-09 | 2015-03-12 | Calixa Therapeutics, Inc. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
| US8906898B1 (en) | 2013-09-27 | 2014-12-09 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
| WO2015051101A1 (en) | 2013-10-02 | 2015-04-09 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
| BE1021242B1 (nl) * | 2014-06-11 | 2015-09-08 | Neogen N.V. | Teicoplanine lyofilisaten |
| KR102603756B1 (ko) | 2014-11-06 | 2023-11-16 | 셀리아 파마슈티칼즈 에이피에스 | 글리코펩티드 조성물 |
| JP2019510076A (ja) * | 2016-02-19 | 2019-04-11 | フォルシュングスツェントルム ボルシュテル ライプニッツツェントルム フュール メディツィン ウント ビオヴィッセンシャフテン | 細菌感染症を治療するための手段と方法 |
| EP3454883A1 (en) | 2016-05-09 | 2019-03-20 | Xellia Pharmaceuticals ApS | Stabilized glycopeptide antibiotic formulations |
| CN107661470A (zh) * | 2016-08-29 | 2018-02-06 | 成都特兰辰亚生物科技有限公司 | 添加有萘夫西林钠治疗痢疾的组合物 |
| EP4192247A4 (en) * | 2020-08-04 | 2025-01-08 | Harrow IP, LLC | Antibacterial compositions and methods for fabricating thereof |
| US12343373B2 (en) | 2020-10-30 | 2025-07-01 | Somerset Therapeutics, Llc | Glycopeptide antibiotics liquid formulations and methods and uses thereof |
| EP4014965A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| EP4014969A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| CN117899225A (zh) * | 2024-01-19 | 2024-04-19 | 芮城绿曼生物药业有限公司 | 一种增强免疫力的兽用抗菌注射剂、制备方法及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775533A (en) * | 1987-02-24 | 1988-10-04 | Erbamont, Inc. | Reconstitution of dry fill cyclophosphamide |
| US6660267B1 (en) * | 1992-12-21 | 2003-12-09 | Promega Corporation | Prevention and treatment of sepsis |
| GB9500978D0 (en) * | 1995-01-19 | 1995-03-08 | Smithkline Beecham Plc | Pharmaceutical formulations |
| CZ75597A3 (en) * | 1995-07-17 | 1997-08-13 | Fraunhofer Ges Forschung | Biologically active, metal containing ribonucleotide polypeptide, process of its preparation and pharmaceutical composition containing thereof |
| JP4142149B2 (ja) * | 1997-07-10 | 2008-08-27 | 明治製菓株式会社 | バンコマイシンの凍結乾燥製剤 |
| US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| CA2413251C (en) * | 2000-06-21 | 2012-06-12 | Cubist Pharmaceuticals, Inc. | Compositions and methods to improve the oral absorption of antimicrobial agents |
| US7378408B2 (en) * | 2001-11-30 | 2008-05-27 | Pfizer Inc. | Methods of treatment and formulations of cephalosporin |
| US6900184B2 (en) | 2003-04-14 | 2005-05-31 | Wyeth Holdings Corporation | Compositions containing pipercillin and tazobactam useful for injection |
-
2006
- 2006-02-08 PT PT67113704T patent/PT1848413E/pt unknown
- 2006-02-08 EP EP06711370.4A patent/EP1848413B1/en not_active Expired - Lifetime
- 2006-02-08 ES ES06711370.4T patent/ES2482700T3/es not_active Expired - Lifetime
- 2006-02-08 NZ NZ555077A patent/NZ555077A/en not_active IP Right Cessation
- 2006-02-08 UA UAA200708619A patent/UA91208C2/ru unknown
- 2006-02-08 WO PCT/IN2006/000044 patent/WO2006085337A1/en not_active Ceased
- 2006-02-08 AU AU2006213441A patent/AU2006213441B2/en not_active Ceased
- 2006-02-08 US US11/816,179 patent/US7960337B2/en not_active Expired - Fee Related
- 2006-02-08 JP JP2007554741A patent/JP4918502B2/ja not_active Expired - Fee Related
- 2006-02-08 BR BRPI0607168-6A patent/BRPI0607168A2/pt not_active IP Right Cessation
- 2006-02-08 MX MX2007009754A patent/MX2007009754A/es active IP Right Grant
- 2006-02-08 CN CNA2006800013537A patent/CN101080221A/zh active Pending
- 2006-02-08 CA CA2597812A patent/CA2597812C/en not_active Expired - Fee Related
- 2006-02-08 KR KR1020077012489A patent/KR20070085674A/ko not_active Ceased
- 2006-02-08 KR KR1020097006944A patent/KR20090052893A/ko not_active Withdrawn
-
2007
- 2007-05-29 ZA ZA200704393A patent/ZA200704393B/xx unknown
-
2011
- 2011-04-27 US US13/095,665 patent/US8778873B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NZ555077A (en) | 2010-03-26 |
| ES2482700T3 (es) | 2014-08-04 |
| PT1848413E (pt) | 2014-07-18 |
| CN101080221A (zh) | 2007-11-28 |
| WO2006085337B1 (en) | 2006-11-02 |
| WO2006085337A1 (en) | 2006-08-17 |
| MX2007009754A (es) | 2007-11-07 |
| AU2006213441B2 (en) | 2011-12-01 |
| KR20090052893A (ko) | 2009-05-26 |
| JP2008530082A (ja) | 2008-08-07 |
| US20080188403A1 (en) | 2008-08-07 |
| JP4918502B2 (ja) | 2012-04-18 |
| US8778873B2 (en) | 2014-07-15 |
| AU2006213441A1 (en) | 2006-08-17 |
| EP1848413A1 (en) | 2007-10-31 |
| US7960337B2 (en) | 2011-06-14 |
| EP1848413B1 (en) | 2014-04-09 |
| CA2597812C (en) | 2012-01-24 |
| BRPI0607168A2 (pt) | 2009-08-11 |
| ZA200704393B (en) | 2008-09-25 |
| CA2597812A1 (en) | 2006-08-17 |
| UA91208C2 (ru) | 2010-07-12 |
| US20110257079A1 (en) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8778873B2 (en) | Parenteral combination therapy for infective conditions with drug resistant bacterium | |
| ES2994966T3 (en) | Single doses of oritavancin for treating or preventing a bacterial infection | |
| EP2062581B1 (en) | The antibiotics composition comprising beta-lactam antibiotics and ionic chelating agents | |
| KR100900208B1 (ko) | 감염의 치료에 대해 토탈 솔루션을 제공하는 항생제 배합물 | |
| JP2008540515A (ja) | 嚢胞性線維症を含む重症感染症の処置および管理 | |
| Fortner et al. | Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions | |
| CN121419770A (zh) | 包含抗细菌剂的药物组合及其组合物 | |
| WO2013042140A2 (en) | Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement | |
| ES2690725T3 (es) | Composiciones que comprenden cefepima y tazobactam | |
| RU2521391C2 (ru) | Новые однократные единичные составы карбапенема и аминогликозида | |
| KR20110095856A (ko) | 아즈트레오남과 카르바페넴류인 메로페넴 및 에르타페넴의 상승작용적 조합 | |
| JP6552648B2 (ja) | 抗菌組成物 | |
| WO2024079094A1 (en) | Methods of treating staphylococcus aureus bacteremia infections | |
| Pezzani | Cefuroxime | |
| Eichenwald | Antimicrobial therapy in children |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20070601 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20080908 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20090202 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20080908 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20090304 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20090202 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20100930 Appeal identifier: 2009101001975 Request date: 20090304 |
|
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20090403 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20090403 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20090304 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20081203 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20080820 Patent event code: PB09011R02I |
|
| B601 | Maintenance of original decision after re-examination before a trial | ||
| E801 | Decision on dismissal of amendment | ||
| PB0601 | Maintenance of original decision after re-examination before a trial |
Comment text: Report of Result of Re-examination before a Trial Patent event code: PB06011S01D Patent event date: 20090415 |
|
| PE0801 | Dismissal of amendment |
Patent event code: PE08012E01D Comment text: Decision on Dismissal of Amendment Patent event date: 20090415 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20090403 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20081203 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20080820 |
|
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090304 Effective date: 20100930 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20100930 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20090304 Decision date: 20100930 Appeal identifier: 2009101001975 |